IDH2 and central nervous system cancer: In the end, the build model was able to achieve an accuracy of 0.85 for the training and 0.87 for the validation set in terms of predicting IDH mutation status of grade II/III gliomas, which is comparable or superior to previous reports as the current report performed the accuracy of the built model using a validation dataset.